I did my PhD at Uppsala University, Dept. of Medical Biochemistry and Microbiology, in 2006 and in my thesis work I focused on the biosynthesis of the glycosaminoglycan heparan sulphate.
In 2011 I started as a postdoc at KI, and since 2012 I have a Research Associate position (forskarassistent).
Alzheimer's disease (AD) is the most common form of dementia and one of the hallmarks of its pathobiology are misfolding of the amyloid-b peptide, which forms amyloid plaques in the brain of AD patients.
In my research group we are studying the BRICHOS domain, which is one of Nature’s solutions of preventing aggregation of amyloid forming proteins. We have been able to show that the BRICHOS domain very efficiently inhibits aggregation of the amyloid-beta peptide in vitro, and these promising results gave us the idea of exploring BRICHOS as a treatment strategy for Alzheimer’s disease (AD). In order to investigate if BRICHOS also could inhibit amyloid-beta aggregation and its neurotoxicity in vivo, we have previously used transgenic Drosophila melanogaster (fruit fly). In the fruit fly model aggregation of amyloid-beta leads to neurotoxicity and we are investigating if different BRICHOS domains can prevent this, in the fly brain. We are also studying the BRICHOS mechanism of action using biochemistry and cell biology methodology.
Our results so far are very promising and our goal is to investigate the possibility to harness the endogenous protective component BRICHOS, in the fight against Alzheimer’s disease.